28th Luglio 2023 Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
25th Luglio 2023 Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
21st Luglio 2023 Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
21st Luglio 2023 Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)